Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;39(3):e70116.
doi: 10.1111/ctr.70116.

Innovative Trajectory Analysis Reveals Dynamics and Risk Factors of Post-Kidney Transplant Diabetes Mellitus in a French Cohort

Affiliations

Innovative Trajectory Analysis Reveals Dynamics and Risk Factors of Post-Kidney Transplant Diabetes Mellitus in a French Cohort

Julie Olabe et al. Clin Transplant. 2025 Mar.

Abstract

Background and hypothesis: Post-transplant diabetes mellitus (PTDM) is a common, dynamic complication after kidney transplantation (KT) that may resolve over time. To better understand and prevent PTDM, we analyzed its prevalence, evolution, and influencing factors.

Methods: Data from the French national ASTRE database at different post-transplantation periods (P) were analyzed. PTDM was defined by fasting blood glucose (FBG) ≥1.26 g/L, HbA1c ≥ 6.5%, or the use of hypoglycemic medications in kidney transplant recipients without diabetes. Patient trajectories were identified using group-based trajectory models (GBTM), and associated factors were examined.

Results: Among 2898 patients, PTDM prevalence was 27.3% at P1 (>M2, ≤M6), 21.3% at P2 (>M6, ≤M18), 19.8% at P3 (>M18, ≤M30), and 19.9% at P4 (>M30, ≤M42). Analysis of 1825 patients identified four trajectories: no PTDM (67%), late-onset PTDM (6%), remission after P1 (10%), and early, persistent PTDM (17%). Late-onset PTDM was linked to history of cardiovascular disease, higher BMI at transplantation, HCV positive status, and weight gain. Early, persistent PTDM was associated with older age, higher BMI, HVC positive status, history of cardiovascular disease, and tacrolimus use. PTDM remission was linked to lower BMI. Corticosteroids contributed to both late-onset and persistent PTDM, while switching between tacrolimus and cyclosporine did not significantly affect progression.

Conclusion: This study confirmed the high prevalence and dynamic nature of PTDM after transplantation, emphasizing the critical role of pretransplant cardiovascular disease, BMI, and early post-transplant weight gain in the onset or remission of PTDM.

Keywords: Organ Procurement and Transplantation Network (OPTN); diabetes; kidney disease: metabolic; new onset post‐transplant diabetes; statistics.

PubMed Disclaimer

References

    1. Agence de la biomédecine, Rapport médical et scientifique Illustration 2023, accessed March 20, 2021, https://www.agence-biomedecine.fr/Rapports-d-activite.
    1. C. J. Yates, S. Fourlanos, J. Hjelmesæth, et al., “New‐Onset Diabetes After Kidney Transplantation—Changes and Challenges,” American Journal of Transplantation 12 (2012): 820–8282.
    1. A. Sharif, H. Chakkera, A. de Vries, et al., “International Consensus on Post‐Transplantation Diabetes Mellitus,” Nephrology, Dialysis, Transplantation 39 (2024): 531–549.
    1. E. Porrini, J. M. Diaz, F. Moreso, et al., “Prediabetes is a Risk Factor for Cardiovascular Disease Following Renal Transplantation,” Kidney International 96 (2019): 1374–1380.
    1. I. A. Eide, T. A. S. Halden, A. Hartmann, et al., “Mortality Risk in Post‐Transplantation Diabetes Mellitus Based on Glucose and HbA1c Diagnostic Criteria,” Transplant International: Official Journal of the European Society for Organ Transplantation 29 (2016): 568–578.

MeSH terms

LinkOut - more resources